Non-alcoholic fatty liver disease (NAFLD), insulin resistance and lipid profile in antiepileptic drug treatment

Luef, Gerhard; Rauchenzauner, Markus; Waldmann, Markus; Sturm, Wolfgang; Sandhofer, A.; Seppi, Klaus; Trinka, Eugen; Unterberger, Iris; Ebenbichler, Christoph; Joannidis, Michael; Walser, Gerald; Bauer, Gerhard; Hoppichler, Fritz; Lechleitner, Monika

doi:10.1016/j.eplepsyres.2009.04.004

Cited by 83 publications

(53 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This modification of lipid profile is particularly significant among CBZ and polytherapy group than VPA group. Similar results were reported by other studies [17,18,19,20]. In this respect, it has been reported that chronic treatment with AEDs may compete with cholesterol in the utilization of hepatic microsomal enzymes P-450 system leading to reduction in the transformation of cholesterol to bile acids resulting in increase in serum cholesterol level [21] while Hsieh et al [22] reported that enzyme-inducing AEDs like CBZ increase the activity of the hepatic cytochrome P450 system, which is involved in synthesis of serum cholesterol, though direct studies are needed, our findings are wholly consistent with this hypothesis.…”

Section: Discussionsupporting

confidence: 82%

The Predictors of Early Atherosclerosis in Young Adult Epileptic Patients

Soliman

Yousef

Fattah

et al. 2016

Zagazig University Medical Journal

View full text Add to dashboard Cite

Background: Patients with epilepsy develope a wide range of medical and neurologic disorders, compared with the general population. The association between epilepsy and atherosclerosis is not clearly defined. Several studies claims that epileptic patients may have the risk to develop atherosclerosis. Methods: This study included 40 adult epileptic and 40 control subjects. For all, Common carotid artery intima media thickness (CA-IMT), fasting lipid profile, serum uric acid (SUA), C -reactive protein (CRP) and glutathione peroxidase (GPX), were assessed. Results: Total cholesterol (TC) ,low density lipoproteins (LDL), Total Triglycerides (TG) ,CRP, GPX were significantly higher in patients compared to control. CA-IMT was significantly higher in epileptic patients treated with antiepileptic drugs (AEDS) compared to control group. The longer the duration of AEDs the thicker was the CA-IMT. Conclusions: Our results heightened atherosclerotic risk in patients with epilepsy on AEDS.

show abstract

Section: Discussionsupporting

confidence: 82%

The Predictors of Early Atherosclerosis in Young Adult Epileptic Patients

Soliman

Yousef

Fattah

et al. 2016

Zagazig University Medical Journal

View full text Add to dashboard Cite

show abstract

“…The increase in body weight is associated with metabolic complications including hyperlipidemia, hypertension, insulin resistance and diabetes, atherosclerosis, and reproductive disorders related to increased serum androgens [120,121]. Ultrasound evidence of fatty liver is also reported in more than 30 % of adolescents [122] and in about 60 % of adults treated with valproate [123]. The etiology of weight gain during valproic acid treatment is not fully understood, but many possible contributing mechanisms have been proposed.…”

Section: Management Of Seizuresmentioning

confidence: 95%

Common Medications Which Lead to Unintended Alterations in Weight Gain or Organ Lipotoxicity

Medici

McClave

Miller

2015

Curr Gastroenterol Rep

View full text Add to dashboard Cite

Obesity is one of the most common chronic conditions in the world. Its management is difficult, partly due to the multiple associated comorbidities including fatty liver, diabetes, hypertension, and hyperlipidemia. As a result, the choice of prescription medications in overweight and obese patients has important implications as some of them can actually worsen the fat accumulation and its associated metabolic complications. Several prescription medications are associated with weight gain with mechanisms that are often poorly understood and under-recognized. Even less data are available on the distribution of fat and lipotoxicity (the organ damage related to fat accumulation). The present review will discuss the drugs associated with weight gain, their mechanism of action, and the magnitude and timing of their effect.

show abstract

“…We JOURNAL OF BIOLOGICAL CHEMISTRY 28903 exposed a mouse hepatoma line, Hepa-1c1c7, to the KDACi VPA in the presence and absence of Dex and measured expression of these genes by RT-qPCR. We chose VPA because it is clinically relevant and causes reproductive and metabolic side effects that suggest an impact on nuclear receptor signaling (13,28,29). Our analysis identified four genes at which VPA impaired Dex-activated gene expression as shown in Fig.…”

Section: Effects Of Vpa Treatment On Expression Of Gr-regulatedmentioning

confidence: 97%

“…KDACis are currently being investigated for potential use in treating a variety of additional diseases, including HIV, inflammatory disorders, and neurological disorders, and thus, their use in humans may eventually expand (3,11). VPA has been used clinically for over 30 years and has been found to cause metabolic and reproductive side effects in about 50% of users (12,13). Our general lack of knowledge about the functions of Class I and II KDACs in signaling is an obstacle to understanding the physiological impact of these drugs and to improving their usage so that benefits are maximized and unwanted side effects are minimized.…”

mentioning

confidence: 99%